Guo's Endovascular Aortic Arch Replacement of Aortic Dissection by WeFlow-Tribranch Endoprothesis: a Multicenter Pilot Study(GRAFT Study)

Aortic Aneurysm and Dissection Clinical Trial

Official title:

Guo's Endovascular Aortic Arch Replacement of Aortic Dissection by WeFlow-Tribranch Endoprothesis: a Multicenter Pilot Study(Graft Study)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05754541
• Other study ID #: WeFlow-Tribranch V1.0
• Status: Recruiting
• Phase: N/A
• Start date: November 10, 2022
• Est. completion date: December 31, 2025

Study information

• Verified date: July 2023
• Source: Hangzhou Endonom Medtech Co., Ltd.
• Contact: Wei Guo
• Phone: 13611129129
• Email: Pla301dml[@]vip.sina.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To explore the effect and prognosis of endovascular interventional therapy in high-risk patients with aortic arch dissection and aneurysm

Description:

The WeFlow-Tribranch Aortic Arch Stent Graft System first in man study is a prospective, multi-center, single arm trial, which will enroll a total of 20 patients. The goal of this study is to evaluate the safety and efficacy of WeFlow-Tribranch Aortic Arch Stent Graft System in the treatment of patients with aortic arch dissection and aneurysm.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Patients aged 18 to 80 years old.

2. The patient was diagnosed with subacute or chronic aortic arch dissection, or Aortic arch aneurysms.

3. Patients showing a suitable vascular condition, including:

1. Ascending aorta length greater than 50 mm (from the aortic sinusoid junction to the proximal cardiac margin of the innominate artery).

2. Ascending aorta diameter = 24 mm and = 48 mm;

3. Proximal anchoring zone length = 30 mm;

4. Innominate artery diameter = 24 mm and = 7 mm, length = 20 mm;

5. Left common carotid artery or left subclavian artery diameter = 24 mm and = 7 mm, length = 20 mm;

6. Suitable arterial access for endovascular interventional treatment ;

4. Patients able to understand the purpose of the trial, participate in the trial voluntarily with informed consent form signed by the subject him/herself or his or her legal representative, and willing to complete follow-up visits as required under the protocol.

5. Patients evaluated by at least two vascular surgeons or cardiac surgeons as high surgical risk patients or deemed to have significant surgical contraindications. (The recommended reference criteria are: EuroSCORE score = 6, or CFS score > 4, or ASA grade 3-4, or there are other high-risk surgical factors that affect the prognosis of the subject, such as patients with a history of open surgery, other high-risk factors judged by a physician team, or patients who refuse open surgery.)

Exclusion Criteria:

1. Patients that have experienced systemic infection during past three months;

2. Neck surgery was performed within three months;

3. Infectious aortic disease?Takayasu arteritis,Marfan syndrome (or other connective tissue diseases );

4. Patients with severe stenosis, calcification, thrombosis or tortuosity of the Brachiocephalic trunk, Left common carotid artery or left subclavian artery;

5. Heart transplant patients;

6. Patients that have suffered MI or stroke during past three months;

7. Patients with Class IV heart function (NYHA classification) or LVEF<30%

8. Active peptic ulcers or upper gastrointestinal bleeding occurring within the previous three months;

9. Hematological abnormality, defined as follows: Leukopenia (WBC < 3 × 109/L), acute anemia (Hb < 90 g/L); thrombocytopenia (PLT count < 50 × 109/L);

10. Patients with renal insufficiency, serum creatinine > 150 umol/l (or 3.0 mg/dl) and / or end-stage renal disease requiring renal dialysis shall be determined by the investigator after comprehensive analysis;

11. Subjects with severe liver dysfunction and ALT or AST exceeding 3 times the upper limit of normal; Subjects whose serum total bilirubin (STB) exceeds 2 times the upper limit of normal;

12. Patients with intestinal necrosis and lower limb ischemic necrosis;

13. Paraplegic patients;

14. Patients that are pregnant or breastfeeding;

15. Patients with allergies to contrast agents;

16. Patients with a life expectancy of less than 12 months;

17. Patients currently participating in other drug or device research;

18. Any other disease or abnormality that the investigators believe may hinder endovascular interventional treatment.

Related Conditions & MeSH terms

• Aneurysm
• Aortic Aneurysm
• Aortic Aneurysm and Dissection
• Aortic Dissection

Intervention

Device:
• WeFlow-Tribranch Aortic Arch Stent Graft System
Endovascular treament in patients with aortic arch dissection and aneurysm by WeFlow-Tribranch Aortic Arch Stent Graft System

Locations

Country	Name	City	State
China	Chinese PLA Gencral Hosptial	Beijing	Beijing
China	West China Hospital of Sichuan University	Chengdu	Sichuan
China	Nanjing First Hospital	Nanjing	Jiangsu
China	Zhongshan Hospital, Fudan University	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Hangzhou Endonom Medtech Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	All-cause mortality and major stroke within 12 months after surgery.	All-cause mortality includes cardiac mortality, non-cardiac mortality and mortality from unknown causes. Severe stroke is defined as a modified Rankin score (mRS) = 2 at 90 days following stroke onset	12 months post-intervention
Secondary	Aortic-related mortality within 12 months post operation.	Refers to mortality caused by a ruptured aortic dissection/aneurysm or endovascular interventional treatment.	within 12 months post operation
Secondary	Aortic remodeling results.	Compare the results of CTA before operation and on the 30th day, 6th month and 12th month after operation, the expansion of the true lumen and the thrombosis of the false lumen at the coverage of the aortic dissection vascular stent to determine whether the blood vessel is successfully remodeled,or CTA reexamination 12 months after operation showed that the maximum diameter of Aortic aneurysm increased by = 5 mm compared with that before operation.	1 month, 6 months and 12 months post-intervention
Secondary	Major adverse events occurring within 30 days after surgery.	Refers to all-cause mortality, myocardial infarction, ischemic stroke or respiratory failure occurring within 30 days after surgery. More specifically, myocardial infarction refers to a drastic reduction or complete interruption of the coronary blood supply due to coronary artery disease, resulting in severe and prolonged acute ischemia of the corresponding myocardium, leading to necrosis of cardiomyocytes. Ischemic stroke refers to the end result of necrosis of brain tissue caused by narrowing or occlusion of the arteries supplying blood to the brain or insufficient blood supply to the brain. Respiratory failure is defined as a state resulting in significantly prolonged intubation, tracheotomy, deterioration of lung function, or other fatal outcomes.	within 30 days after surgery
Secondary	Incidence of severe adverse events.	Refers to an event that occurs during the clinical trial that results in mortality or serious deterioration in patient health, including a fatal illness or injury, a permanent defect in body structure or body function, or an event that requires medical or surgical intervention to avoid one or more permanent defects in body structure or body function.	within 12 months post-intervention